MGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants

Neuropharmacology

Volumn 66, Issue , 2013, Pages 40-52

  Chaki, Shigeyuki ^a   Ago, Yukio ^b   Palucha Paniewiera, Agnieszka ^c   Matrisciano, Francesco ^d,e   Pilc, Andrzej ^c,f  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d UNIVERSITY OF ILLINOIS   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Depression; Ketamine; mGlu2 3 receptor; mGlu5 receptor

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 [3 (2,6 DIMETHYLPYRIDIN 4 YL)PHENYL] 7 METHYL 8 TRIFLUOROMETHYL 1,3 DIHYDROBENZO[B][1,4]DIAZEPIN 2 ONE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 5 HYDROXYTRYPTOPHAN; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; AZD 2066; BRAIN DERIVED NEUROTROPHIC FACTOR; EGLUMETAD; FENOBAM; GLUTAMIC ACID; GRN 529; IMIPRAMINE; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; N [4 [(2 (TRIFLUOROMETHYL) 3 HYDROXY 4 (ISOBUTYRYL)PHENOXY)]METHYL]; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT; RG 1578; RG 7090; RO 4491533; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; DEPRESSION; DRUG EFFICACY; DRUG POTENTIATION; GABAERGIC TRANSMISSION; HUMAN; LATENT PERIOD; LONG TERM POTENTIATION; MONOAMINERGIC SYSTEM; NERVE CELL NETWORK; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUICIDAL IDEATION; TACHYPHYLAXIS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID AGENTS; HUMANS; KETAMINE; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, METABOTROPIC GLUTAMATE; SYNAPTIC TRANSMISSION;

EID: 84872166978     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.05.022     Document Type: Review

References (157)

1. W.M. Abisaab, M. Bubser, R.H. Roth, and A.Y. Deutch 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex Neuropsychopharmacology 20 1999 92 96
2. A. Ahnaou, F.M. Dautzenberg, H. Geys, H. Imogai, A. Gibelin, D. Moechars, T. Steckler, and W.H. Drinkenburg Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture Eur. J. Pharmacol. 603 2009 62 72
3. A. Alt, E.S. Nisenbaum, D. Bleakman, and J.M. Witkin A role for AMPA receptors in mood disorders Biochem. Pharmacol. 71 2006 1273 1288
4. P. Andlin-Sobocki, B. Jonsson, H.U. Wittchen, and J. Olesen Cost of disorders of the brain in Europe Eur. J. Neurol. 1 12 Suppl. 2005 1 27
5. R. Anwyl Metabotropic glutamate receptors: electrophysiological properties and role in plasticity Brain Res. Brain Res. Rev. 29 1999 83 120
6. S. Attucci, V. Carla, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol 132 2001 799 806
7. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
8. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur. Neuropsychopharmacol. 17 2007 172 179
9. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
10. E. Berry-Kravis, D. Hessl, S. Coffey, C. Hervey, A. Schneider, J. Yuhas, J. Hutchison, M. Snape, M. Tranfaglia, D.V. Nguyen, and R. Hagerman A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J. Med. Genet. 46 2009 266 271
11. A. Bespalov, A.L. Jongen-Rêlo, M. van Gaalen, S. Harich, H. Schoemaker, and G. Gross Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs J. Pharmacol. Exp. Ther. 320 2007 944 950
12. A. Bikbaev, S. Neyman, R.T. Ngomba, J. Conn, F. Nicoletti, and D. Manahan-Vaughan MGluR5 mediates the interaction between late-LTP, network activity, and learning Plos One 3 2008 e2155
13. G. Bonanno, R. Giambelli, L. Raiteri, E. Tiraboschi, S. Zappettini, L. Musazzi, M. Raiteri, G. Racagni, and M. Popoli Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus J. Neurosci. 25 2005 3270 3279
14. L.A. Boothby, and P.L. Doering Acamprosate for the treatment of alcohol dependence Clin. Ther. 27 2005 695 714
15. M.J. Bradbury, D.R. Giracello, D.F. Chapman, G. Holtz, H. Schaffhauser, S.P. Rao, M.A. Varney, and J.J. Anderson Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-Adrenal axis activity: interaction with serotonergic systems Neuropharmacology 44 2003 562 572
16. P.R. Brakeman, A.A. Lanahan, R. Obrien, K. Roche, C.A. Barnes, R.L. Huganir, and P.F. Worley Homer: a protein that selectively binds metabotropic glutamate receptors Nature 386 1997 284 288
17. M.L. Brandão, J.A. Lopez-Garcia, F.G. Graeff, and M.H. Roberts Electrophysiological evidence for excitatory 5-HT2 and depressant 5-HT1A receptors on neurones of the rat midbrain tectum Brain Res. 556 1991 259 266
18. B. Campo, M. Kalinichev, N. Lambeng, M.E. Yacoubi, I. Royer-Urios, M. Schneider, C. Legrand, D. Parron, F. Girard, A. Bessif, S. Poli, J.M. Vaugeois, E.L. Poul, and S. Celanire Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression J. Neurogenet. 25 2011 152 166
19. J. Cartmell, and D.D. Schoepp Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 75 2000 889 907
20. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, N. Kawashima, T. Yoshimizu, A. Yasuhara, K. Sakagami, S. Okuyama, S. Nakanishi, and A. Nakazato MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
21. A.S. Chappell, C. Gonzales, J. Williams, M.M. Witte, R.C. Mohs, and R. Sperling AMPA potentiator treatment of cognitive deficits in Alzheimer disease Neurology 68 2007 1008 1012
22. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237
23. N.D.P. Cosford, L. Tehrani, J. Roppe, E. Schweiger, N.D. Smith, J. Anderson, L. Bristow, J. Brodkin, X.H. Jiang, I. McDonald, S. Rao, M. Washburn, and M.A. Varney 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J. Med. Chem. 46 2003 204 206
24. H.E. Covington III, M.K. Lobo, I. Maze, V. Vialou, J.M. Hyman, S. Zaman, Q. LaPlant, E. Mouzon, S. Ghose, C.A. Tamminga, R.L. Neve, K. Deisseroth, and E.J. Nestler Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex J. Neurosci. 30 2010 16082 16090
25. M.S. Cowen, E. Djouma, and A.J. Lawrence The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-Administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems J. Pharmacol. Exp. Ther. 315 2005 590 600
26. J.F. Deakin, J. Lees, S. McKie, J.E. Hallak, S.R. Williams, and S.M. Dursun Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch. Gen. Psychiatry 65 2008 154 164
27. C. de Bodinat, B. Guardiola-Lemaitre, E. Mocaer, P. Renard, C. Munoz, and M.J. Millan Agomelatine, the first melatonergic antidepressant: discovery, characterization and development Nat. Rev. Drug Discov. 9 2010 628 642
28. A. Deschwanden, B. Karolewicz, A.M. Feyissa, V. Treyer, S.M. Ametamey, A. Johayem, C. Burger, Y.P. Auberson, J. Sovago, C.A. Stockmeier, A. Buck, and G. Hasler Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study Am. J. Psychiatry 168 2011 727 734
29. M.J. Detke, M. Rickels, and I. Lucki Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology 121 1995 66 72
30. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate A randomized add-on trial of an N-methyl-d-Aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 2010 793 802
31. A.J. Doherty, M.J. Palmer, Z.A. Bortolotto, A. Hargreaves, A.E. Kingston, P.L. Ornstein, D.D. Schoepp, D. Lodge, and G.L. Collingridge A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices Br. J. Pharmacol. 131 2000 239 244
32. W.C. Drevets Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression Prog. Brain Res. 126 2000 413 431
33. J.M. Dwyer, A.E. Lepack, and R.S. Duman mTOR activation is required for the antidepressant effects of mGluR2/3 blockade Int. J. Neuropsychopharmacol. 24 2011 1 6
34. M. El Yacoubi, S. Bouali, D. Popa, L. Naudon, I. Leroux-Nicollet, M. Hamon, J. Costentin, J. Adrien, and J.M. Vaugeois Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression Proc. Natl. Acad. Sci. U S A 100 2003 6227 6232
35. K.A. Emmitte Recent advances in the design and development of novel negative allosteric modulators of mGlu(5) ACS Chem. Neurosci. 2 2011 411 432
36. I. Feinberg, I.G. Campbell, D.D. Schoepp, and K. Anderson The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat Pharmacol. Biochem. Behav. 73 2002 467 474
37. I. Feinberg, D.D. Schoepp, K.C. Hsieh, N. Darchia, and I.G. Campbell The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-Amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-Aminobicyclo[3.1.0]hexane-4, 6-dicarboxylate] in rats J. Pharmacol. Exp. Ther. 312 2005 826 833
38. A. Fekadu, S.C. Wooderson, K. Markopoulo, C. Donaldson, A. Papadopoulos, and A.J. Cleare What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies J. Affect. Disord. 116 2009 4 11
39. M.J. Fell, J.M. Witkin, J.F. Falcone, J.S. Katner, K.W. Perry, J. Hart, L. Rorick-Kehn, C.D. Overshiner, K. Rasmussen, S.F. Chaney, M.J. Benvenga, X. Li, D.L. Marlow, L.K. Thompson, S.K. Luecke, K.A. Wafford, W.F. Seidel, D.M. Edgar, A.T. Quets, C.C. Felder, X. Wang, B.A. Heinz, A. Nikolayev, M.S. Kuo, D. Mayhugh, A. Khilevich, D. Zhang, P.J. Ebert, J.A. Eckstein, B.L. Ackermann, S.P. Swanson, J.T. Catlow, R.A. Dean, K. Jackson, S. Tauscher-Wisniewski, G.J. Marek, J.M. Schkeryantz, and K.A. Svensson N-(4-((2-(trifluoromethyl)-3-hydroxy- 4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes J. Pharmacol. Exp. Ther. 336 2011 165 177
40. A.M. Feyissa, W.L. Woolverton, J.J. Miguel-Hidalgo, Z. Wang, P.B. Kyle, G. Hasler, C.A. Stockmeier, A.H. Iyo, and B. Karolewicz Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 279 283
41. K.C. Fone, and M.V. Porkess Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders Neurosci. Biobehav. Rev. 32 2008 1087 1102
42. P. Gass mGluR5 expression in rodent models of depression and anxiety Curr. Neuropharmacol. 9 2011 23
43. K. Golembiowska, and A. Dziubina Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex Pol. J. Pharmacol. 52 2000 441 448
44. A. Gravius, M. Pietraszek, D. Schafer, W.J. Schmidt, and W. Danysz Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning Behav. Pharmacol. 16 2005 113 121
45. A. Gravius, M. Pietraszek, A. Dekundy, and W. Danysz Metabotropic glutamate receptors as therapeutic targets for cognitive disorders Curr. Top. Med. Chem. 10 2010 187 206
46. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, S.A. Leong, S.W. Lowe, P.A. Berglund, and P.K. Corey-Lisle The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64 2003 1465 1475
47. J.L. Griffiths, and T.A. Lovick Co-localization of 5-HT(2A)-receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat Neurosci. Lett. 326 2002 151 154
48. A.L. Halberstadt, V.D. Lehmann-Masten, M.A. Geyer, and S.B. Powell Interactive effects of mGlu5 and 5-HT(2A) receptors on locomotor activity in mice Psychopharmacology 215 2011 81 92
49. B.R. Harris, M.A. Prendergast, D.A. Gibson, D.T. Rogers, J.A. Blanchard, R.C. Holley, M.C. Fu, S.R. Hart, N.W. Pedigo, and J.M. Littleton Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors Alcohol Clin. Exp. Res. 26 2002 1779 1793
50. K. Hashimoto The role of glutamate on the action of antidepressants Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1558 1568
51. C.A. Heidbreder, M. Bianchi, L.P. Lacroix, S. Faedo, E. Perdona, R. Remelli, P. Cavanni, and F. Crespi Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo Synapse 50 2003 269 276
52. Z.A. Hughes, S.J. Neal, D.L. Smith, S.J. Sukoff Rizzo, C.M. Pulicicchio, S. Lotarski, S. Lu, J.M. Dwyer, J. Brennan, M. Olsen, C.N. Bender, E. Kouranova, T.H. Andree, J.E. Harrison, G.T. Whiteside, D. Springer, S.V. O'Neil, S.K. Leonard, L.E. Schechter, J. Dunlop, S. Rosenzweig-Lipson, and R.H. Ring Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression Neuropharmacology 66 2013 202 214
53. L. Ibrahim, N. Diazgranados, D.A. Luckenbaugh, R. Machado-Vieira, J. Baumann, A.G. Mallinger, and C.A. Zarate Rapid decrease in depressive symptoms with an N-methyl-D-Aspartate antagonist in ECT-resistant major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1155 1159
54. T.M. Itil, P.A. Seaman, M. Huque, S. Mukhopadhyay, D. Blascutti, K.T. NQ, and P.E. Ciccione The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study Curr. Ther. Res. 26 1978 708 724
55. A.H. Iyo, A.M. Feyissa, A. Chandran, M.C. Austin, S. Regunathan, and B. Karolewicz Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat hippocampus Neuroscience 169 2010 1567 1574
56. W. Jacob, A. Gravius, M. Pietraszek, J. Nagel, I. Belozertseva, E. Shekunova, A. Malyshkin, S. Greco, C. Barberi, and W. Danysz The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning Neuropharmacology 57 2009 97 108
57. S. Jacquemont, A. Curie, V. des Portes, M.G. Torrioli, E. Berry-Kravis, R.J. Hagerman, F.J. Ramos, K. Cornish, Y.S. He, C. Paulding, G. Neri, F. Chen, N. Hadjikhani, D. Martinet, J. Meyer, J.S. Beckmann, K. Delange, A. Brun, G. Bussy, F. Gasparini, T. Hilse, A. Floesser, J. Branson, G. Bilbe, D. Johns, and B. Gomez-Mancilla Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056 Sci. Transl. Med. 3 2011 64ra1
58. M.P. Johnson, D. Barda, T.C. Britton, R. Emkey, W.J. Hornback, G.E. Jagdmann, D.L. McKinzie, E.S. Nisenbaum, J.P. Tizzano, and D.D. Schoepp Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) Psychopharmacology (Berl) 179 2005 271 283
59. J. Karasawa, T. Shimazaki, N. Kawashima, and S. Chaki AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist Brain Res. 1042 2005 92 98
60. J. Karasawa, T. Yoshimizu, and S. Chaki A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell Neurosci. Lett. 393 2006 127 130
61. J. Karasawa, M. Kotani, D. Kambe, and S. Chaki AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell Neurochem. Int. 57 2010 615 619
62. T. Kawasaki, Y. Ago, K. Yano, R. Araki, Y. Washida, H. Onoe, S. Chaki, A. Nakazato, H. Hashimoto, A. Baba, K. Takuma, and T. Matsuda Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice Neuropharmacology 60 2011 397 404
63. N. Kawashima, J. Karasawa, T. Shimazaki, S. Chaki, S. Okuyama, A. Yasuhara, and A. Nakazato Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors Neurosci. Lett. 378 2005 131 134
64. J.P. Kelly, A.S. Wrynn, and B.E. Leonard The olfactory bulbectomized rat as a model of depression: an update Pharmacol. Ther. 74 1997 299 316
65. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang The epidemiology of major depressive disorder-results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105
66. I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, and B.T. Johnson Initial severity and antidepressant benefits: a meta-Analysis of data submitted to the Food and Drug Administration PLoS. Med. 5 2008 0260 0268
67. R.J. Knapp, R. Goldenberg, C. Shuck, A. Cecil, J. Watkins, C. Miller, G. Crites, and E. Malatynska Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model Eur. J. Pharmacol. 440 2002 27 35
68. H. Koike, M. Iijima, and S. Chaki Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behav. Brain Res. 224 2011 107 111
69. H. Koike, M. Iijima, and S. Chaki Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists Neuropharmacology 61 2011 1419 1423
70. J.H. Krystal, S.J. Mathew, D.C. D'Souza, A. Garakani, H. Gunduz-Bruce, and D.S. Charney Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 24 2010 669 693
71. R. Kuhn The treatment of depressive states with G-22355 (imipramine hydrochloride) Am. J. Psychiatry 115 1958 459 464
72. Y.D. Lapierre, and L.K. Oyewumi Fenobam: another anxiolytic? Curr. Ther. Res. 31 1982 95 101
73. T.P. Lapin, and K.F. Oxenkrug Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect Lancet 1 1969 132 136
74. B. Legutko, B. Szewczyk, L. Pomierny-Chamiolo, G. Nowak, and A. Pilc Effect of MPEP treatment on brain-derived neurotrophic factor gene expression Pharmacol. Rep. 58 2006 427 430
75. J.R. Leheste, C. Curcio, L. Baldinger, S. Sarwar, S.M. Zakhary, B.H. Hallas, J.M. Horowitz, and G. Torres Glutamate-based drugs for the treatment of clinical depression Cent. Nervous Syst. Agents Med. Chem. 8 2008 170 176
76. X. Li, A.B. Need, M. Baez, and J.M. Witkin Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J. Pharmacol. Exp. Ther. 319 2006 254 259
77. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
78. N. Li, R.J. Liu, J.M. Dwyer, M. Banasr, B. Lee, H. Son, X.Y. Li, G. Aghajanian, and R.S. Duman Glutamate N-methyl-D-Aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol. Psychiatry 69 2011 754 761
79. H.P. Loomer, J.C. Saunders, and N.S. Kline A clinic and pharmacodynamic evaluation of iproniazid as a psychic energizer Psychiatry Res. Rep. 8 1957 129 141
80. Y.M. Lu, Z.P. Jia, C. Janus, J.T. Henderson, R. Gerlai, J.M. Wojtowicz, and J.C. Roder Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP J. Neurosci. 17 1997 5196 5205
81. R. Lujan, Z. Nusser, J.D.B. Roberts, R. Shigemoto, and P. Somogyi Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus Eur. J. Neurosci. 8 1996 1488 1500
82. S. Maeng, C.A. Zarate Jr.; J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol. Psychiatry 63 2008 349 352
83. J. Maj, E. Przegalinski, and E. Mogilnicka Hypotheses concerning the mechanism of action of antidepressant drugs Rev. Physiol. Biochem. Pharmacol. 100 1984 1 74
84. G.J. Marek Glutamatergic mechanisms in antidepressant treatments Eur. Neuropsychopharmacol. 12 2002 S170 S171
85. B.L. Mason, and C.M. Pariante The effects of antidepressants on the hypothalamic-pituitary-Adrenal axis Drug News Perspect. 19 2006 603 608
86. J.M. Mathiesen, N. Svendsen, H. Braunerosborne, C. Thomsen, and M.T. Ramirez Positive allosteric modulation of the human metabotropic glutamate receptor 4 (HmGluR4) by SIB-1893 and MPEP Br. J. Pharmacol. 138 2003 1026 1030
87. F. Matrisciano, M. Storto, R.T. Ngomba, I. Cappuccio, A. Caricasole, S. Scaccianoce, B. Riozzi, D. Melchiorri, and F. Nicoletti Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus Neuropharmacology 42 2002 1008 1015
88. F. Matrisciano, S. Scaccianoce, P. Del Bianco, I. Panaccione, A.M. Canudas, G. Battaglia, B. Riozzi, R.T. Ngomba, G. Molinaro, R. Tatarelli, D. Melchiorri, and F. Nicoletti Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-Adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands J. Neurochem. 93 2005 1345 1352
89. F. Matrisciano, I. Panaccione, M. Zusso, P. Giusti, R. Tatarelli, L. Iacovelli, A.A. Mathé, S.H. Gruber, F. Nicoletti, and P. Girardi Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? Mol. Psychiatry 12 2007 704 706
90. F. Matrisciano, A. Caruso, R. Orlando, M. Marchiafava, V. Bruno, G. Battaglia, S.H. Gruber, D. Melchiorri, R. Tatarelli, P. Girardi, A.A. Mathè, and F. Nicoletti Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats Neuropharmacology 55 2008 525 531
91. F. Matrisciano, M. Zusso, I. Panaccione, B. Turriziani, A. Caruso, L. Iacovelli, L. Noviello, G. Togna, D. Melchiorri, P. Debetto, R. Tatarelli, G. Battaglia, F. Nicoletti, P. Giusti, and P. Girardi Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis Neuropharmacology 54 2008 428 437
92. M. Molina-Hernandez, N.P. Tellez-Alcantara, J. Perez-Garcia, J.I. Olivera-Lopez, and M.T. Jaramillo Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 1129 1135
93. Y. Morishima, T. Miyakawa, T. Furuyashiki, Y. Tanaka, H. Mizuma, and S. Nakanishi Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice Proc. Natl. Acad. Sci. U S A 102 2005 4170 4175
94. S. Morley-Fletcher, J. Mairesse, A. Soumier, M. Banasr, F. Fagioli, C. Gabriel, E. Mocaer, A. Daszuta, B. McEwen, F. Nicoletti, and S. Maccari Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats Psychopharmacology 217 2011 301 313
95. E. Moryl, W. Danysz, and G. Quack Potential antidepressive properties of amantadine, memantine and bifemelane Pharmacol. Toxicol. 72 1993 394 397
96. D.D. Mott, J.J. Doherty, S. Zhang, M.S. Washburn, M.J. Fendley, P. Lyuboslavsky, S.F. Traynelis, and R. Dingledine Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition Nat. Neurosci. 1 1998 659 667
97. L.H. Muhonen, J. Lonnqvist, K. Juva, and H. Alho Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence J. Clin. Psychiatry 69 2008 392 399
98. J.W. Murrough Ketamine as a novel antidepressant: from synapse to behavior Clin. Pharmacol. Ther. 91 2012 303 309
99. S. Nakanishi Molecular diversity of glutamate receptors and implications for brain function Science 258 1992 597 603
100. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin Metabotropic glutamate receptors: from the workbench to the bedside Neuropharmacology 60 2011 1017 1041
101. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Ann. Rev. Pharmacol. Toxicol. 50 2010 295 322
102. D.M. O'Leary, V. Movsesyan, S. Vicini, and A.I. Faden Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism Br. J. Pharmacol. 131 2000 1429 1437
103. A. Palucha, and A. Pilc Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs Pharmacol. Ther. 115 2007 116 147
104. A. Palucha, P. Branski, K. Tokarski, M. Bijak, and A. Pilc Influence of imipramine treatment on the group I of metabotropic glutamate receptors in CA1 region of hippocampus Pol. J. Pharmacol. 49 1997 495 497
105. A. Palucha, P. Branski, B. Szewczyk, J.M. Wieronska, K. Klak, and A. Pilc Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol. Biochem. Behav. 81 2005 901 906
106. A. Palucha-Poniewiera, P. Branski, J.M. Wieroska, and A. Pilc Potential antidepressant-like activity of a potent and highly selective mGlu5 antagonist MTEP is serotonin-dependent Curr. Neuropharmacol 9 2011 50 51
107. A. Pałucha-Poniewiera, J.M. Wierońska, P. Brański, K. Stachowicz, S. Chaki, and A. Pilc On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039 Psychopharmacology (Berl) 212 2010 523 535
108. H.E. Pigott, A.M. Leventhal, G.S. Alter, and J.J. Boren Efficacy and effectiveness of antidepressants: current status of research Psychother. Psychosom. 79 2010 267 279
109. A. Pilc The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in cerebral cortical slices of rat Biol. Psychiatry 29 1991 347S 348S
110. A. Pilc, and B. Legutko Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain Pol. J. Pharmacol. 47 1995 359 361
111. A. Pilc, P. Branski, A. Palucha, K. Tokarski, and M. Bijak Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region Eur. J. Pharmacol. 349 1998 83 87
112. A. Pilc, A. Klodzinska, P. Branski, G. Nowak, B. Szewczyk, E. Tatarczynska, E. Chojnacka-Wojcik, and J. Wieronska Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 2002 181 187
113. A. Pilc, S. Chaki, G. Nowak, and J.M. Witkin Mood disorders: regulation by metabotropic glutamate receptors Biochem. Pharmacol. 75 2008 997 1006
114. J.P. Pin, and R. Duvoisin The metabotropic glutamate receptors: structure and functions Neuropharmacology 34 1995 1 26
115. J.P. Pin, C. De Colle, A.S. Bessis, and F. Acher New perspectives for the development of selective metabotropic glutamate receptor ligands Eur. J. Pharmacol. 375 1999 277 294
116. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-Aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587
117. R.H. Porter, G. Jaeschke, W. Spooren, T.M. Ballard, B. Buttelmann, S. Kolczewski, J.U. Peters, E. Prinssen, J. Wichmann, E. Vieira, A. Muhlemann, S. Gatti, V. Mutel, and P. Malherbe Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity J. Pharmacol. Exp. Ther. 315 2005 711 721
118. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-Aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J. Clin. Psychopharmacol. 28 2008 631 637
119. P. Raboisson, A. Johnson, A. Jureus, S. Pierrou, D. Wensbo, P. Strom, J. Malmquist, J. Sandell, J.D. Andersson, K. Varnas, C. Halldin, and L. Farde Fenobam binds to sites not recognized by ABP688 and other mGluR5 NAMs, but by AZ11696415 in the primate brain Curr. Neuropharmacology 9 2011 55 56
120. Z. Rogoz, G. Skuza, J. Maj, and W. Danysz Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats Neuropharmacology 42 2002 1024 1030
121. S. Rosenzweig-Lipson, C.E. Beyer, Z.A. Hughes, X. Khawaja, S.J. Rajarao, J.E. Malberg, Z. Rahman, R.H. Ring, and L.E. Schechter Differentiating antidepressants of the future: efficacy and safety Pharmacol. Ther. 113 2007 134 153
122. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, D. Warden, G. Niederehe, M.E. Thase, P.W. Lavori, B.D. Lebowitz, P.J. McGrath, J.F. Rosenbaum, H.A. Sackeim, D.J. Kupfer, J. Luther, and M. Fava Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am. J. Psychiatry 163 2006 1905 1917
123. G. Sanacora, C.A. Zarate, J.H. Krystal, and H.K. Manji Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat. Rev. Drug Discov. 7 2008 426 437
124. G. Sanacora, G. Treccani, and M. Popoli Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Neuropharmacology 62 2012 63 77
125. G. Sansig, T.J. Bushell, V.R. Clarke, A. Rozov, N. Burnashev, C. Portet, F. Gasparini, M. Schmutz, K. Klebs, R. Shigemoto, P.J. Flor, R. Kuhn, T. Knoepfel, M. Schroeder, D.R. Hampson, V.J. Collett, C. Zhang, R.M. Duvoisin, G.L. Collingridge, and H. van Der Putten Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7 J. Neurosci. 21 2001 8734 8745
126. S. Scaccianoce, F. Matrisciano, P. Del Bianco, A. Caricasole, V. Di Giorgi Gerevini, I. Cappuccio, D. Melchiorri, G. Battaglia, and F. Nicoletti Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-Adrenocortical axis Neuropharmacology 44 2003 555 561
127. J.J. Schildkraut The catecholamine hypothesis of affective disorder: a review of supporting evidence Am. J. Psychiatry 122 1965 1032 1039
128. D.D. Schoepp, and G.J. Marek Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord. 1 2002 215 225
129. B. Schulz, M. Fendt, F. Gasparini, K. Lingenhohl, R. Kuhn, and M. Koch The metabotropic glutamate receptor antagonist 2-methyl-6- (Phenylethynyl)- pyridine (MPEP) blocks fear conditioning in rats Neuropharmacology 41 2001 1 7
130. Y. Shirayama, and S. Chaki Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents Curr. Neuropharmacol 4 2006 277 291
131. P. Skolnick, B. Legutko, X. Li, and F.P. Bymaster Current perspectives on the development of non-biogenic amine-based antidepressants Pharmacol. Res. 43 2001 411 422
132. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol. Sci. 30 2009 563 569
133. M. Smialowska, B. Szewczyk, P. Branski, J.M. Wieronska, A. Palucha, M. Bajkowska, and A. Pilc Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus Neuropharmacology 42 2002 1016 1023
134. I. Smolders, R. Clinckers, A. Meurs, D. De Bundel, J. Portelli, G. Ebinger, and Y. Michotte Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-Anticonvulsant action Neuropharmacology 54 2008 1017 1028
135. K. Stachowicz, K. Golembiowska, M. Sowa, G. Nowak, E. Chojnacka-Wojcik, and A. Pilc Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent Neuropharmacology 53 2007 741 748
136. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn, and D.D. Schoepp Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discov. 4 2005 131 144
137. S.M. Szymkowicz, R.M. Dale, and N. Finnegan Reduction of depressive symptoms via repeated intravenous ketamine infusions in three patients with highly treatment-resistant depression Soc. Neurosci. 369 2011 01
138. Y. Tamaru, S. Nomura, N. Mizuno, and R. Shigemoto Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites Neuroscience 106 2001 481 503
139. E. Tatarczynska, A. Klodzinska, E. Chojnacka-Wojcik, A. Palucha, F. Gasparini, R. Kuhn, and A. Pilc Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist Br. J. Pharmacol. 132 2001 1423 1430
140. L.S. Thomas, D.E. Jane, J.R. Harris, and M.J. Croucher Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro Neuropharmacology 39 2000 1554 1566
141. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. Mcgrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, and M. Fava Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
142. R. Trullas, and P. Skolnick Functional antagonists at the NMDA receptor complex exhibit antidepressant actions Eur. J. Pharmacol. 185 1990 1 10
143. J.C. Tu, B. Xiao, S. Naisbitt, J.P. Yuan, R.S. Petralia, P. Brakeman, A. Doan, V.K. Aakalu, A.A. Lanahan, M. Sheng, and P.F. Worley Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins Neuron 23 1999 583 592
144. V.A. Vaidya, and R.S. Duman Depression-emerging insights from neurobiology Br. Med. Bull. 57 2001 61 79
145. J.A. van Hooft, R. Giuffrida, M. Blatow, and H. Monyer Differential expression of group I metabotropic glutamate receptors in functionally distinct hippocampal interneurons J. Neurosci. 20 2000 3544 3551
146. J.M. Wieronska, and A. Pilc Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs Neurochem. Int. 55 2009 85 97
147. J.M. Wieronska, P. Branski, B. Szewczyk, A. Palucha, M. Papp, P. Gruca, E. Moryl, and A. Pilc Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression Pol. J. Pharmacol. 53 2001 659 662
148. J.M. Wieronska, B. Szewczyk, P. Branski, A. Palucha, and A. Pilc Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats Amino Acids 23 2002 213 216
149. J.M. Wierońska, B. Legutko, D. Dudys, and A. Pilc Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus Pharmacol. Rep. 60 2008 844 855
150. J.M. Witkin, G.J. Marek, B.G. Johnson, and D.D. Schoepp Metabotropic glutamate receptors in the control of mood disorders CNS Neurol. Disord. Drug Targets 6 2007 87 100
151. H.U. Wittchen, F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, B. Jonsson, J. Olesen, C. Allgulander, J. Alonso, C. Faravelli, L. Fratiglioni, P. Jennum, R. Lieb, A. Maercker, J. van Os, M. Preisig, L. Salvador-Carulla, R. Simon, and H.C. Steinhausen The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur. Neuropsychopharmacol. 21 2011 655 679
152. 3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain J. Pharmacol. Exp. Ther. 298 2001 453 460
153. 3H]LY459477 autoradiography Neuropharmacology 66 2013 89 98
154. T. Yoshimizu, T. Shimazaki, A. Ito, and S. Chaki An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats Psychopharmacology (Berl) 186 2006 587 593
155. C.A. Zarate, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864
156. F. Zerbib, S.B. des Varannes, S. Roman, R. Tutuian, J.P. Galmiche, F. Mion, J. Tack, P. Malfertheiner, and C. Keywood Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease Aliment. Pharmacol. Ther. 33 2011 911 921
157. F.M. Zhou, and J.J. Hablitz Metabotropic glutamate receptor enhancement of spontaneous IPSCs in neocortical interneurons J. Neurophysiol. 78 1997 2287 2295